DOGP: AI 评分 46/100 — AI 分析 (4月 2026)

Dogecoin Cash, Inc. operates in the telemedicine and cannabis industries, providing online referral services for medical marijuana cards. The company's platform, PrestoDoctor, connects patients with physicians for medical marijuana recommendations.

Key Facts: AI Score: 46/100 Sector: Healthcare

公司概况

概要：

Dogecoin Cash, Inc. focuses on telemedicine services for medical marijuana recommendations through its PrestoDoctor platform, targeting the cannabidiol and cannabis industries. The company develops related products like lozenges and topical creams, and intends to offer fashion apparel through its website, operating in a competitive and evolving regulatory landscape.

DOGP是做什么的？

Dogecoin Cash, Inc., formerly known as Cannabis Sativa, Inc. until its name change in November 2024, is a healthcare information services company providing telemedicine solutions within the cannabis industry. The company's core offering is PrestoDoctor, an online platform that facilitates virtual consultations between patients and physicians for medical marijuana recommendations. Utilizing video conferencing technology, PrestoDoctor aims to streamline the process of obtaining medical marijuana cards for eligible individuals in the United States. Beyond its telemedicine platform, Dogecoin Cash, Inc. develops and markets cannabis-related products, including lozenges designed for relief, Recover, a deep penetrating healing balm, and Trauma Cream, a cannabinoid and THC-infused cream. The company also holds an intellectual property license for the manufacture of medical marijuana edibles. Additionally, Dogecoin Cash, Inc. intends to expand its offerings to include branded men's and women's fashion apparel sourced from suppliers, to be sold through its www.cbds.com website. Headquartered in Mesquite, Nevada, Dogecoin Cash, Inc. serves both the cannabidiol (CBD) and cannabis markets, navigating the complex regulatory environment surrounding these industries.

DOGP的投资论点是什么？

Dogecoin Cash, Inc. presents a high-risk, high-reward investment profile due to its focus on the evolving cannabis telemedicine market. The company's PrestoDoctor platform offers a direct-to-consumer approach for medical marijuana recommendations, potentially capitalizing on increasing acceptance and legalization trends. However, the company's negative P/E ratio of -1.65 and a profit margin of -195.0% indicate significant financial challenges. Growth catalysts include expanding PrestoDoctor's reach to new states and launching planned fashion apparel lines. Key risks involve regulatory hurdles, competition from established telemedicine providers, and the company's limited operating history. Investors should carefully consider the volatile nature of the cannabis industry and Dogecoin Cash, Inc.'s financial position before investing.

DOGP在哪个行业运营？

Dogecoin Cash, Inc. operates within the rapidly evolving cannabis and telemedicine industries. The cannabis market is experiencing significant growth, driven by increasing legalization and acceptance of medical and recreational marijuana. Telemedicine is also expanding, fueled by technological advancements and a growing demand for remote healthcare services. Dogecoin Cash, Inc. aims to capitalize on the intersection of these two trends by providing online medical marijuana recommendations. However, the company faces competition from established telemedicine providers and other cannabis-focused businesses. The industry is also subject to complex and changing regulations, which can impact Dogecoin Cash, Inc.'s operations and growth prospects.

Medical - Healthcare Information Services

Healthcare

DOGP有哪些增长机遇？

Expansion into New States: Dogecoin Cash, Inc. has the opportunity to expand its PrestoDoctor platform into new states as medical marijuana legalization progresses. Each new state represents a potential market for its telemedicine services. The timeline for this expansion depends on the legislative landscape in each state, but successful entry into key markets could significantly boost revenue and market share. This expansion would require navigating different regulatory environments and tailoring its services to meet local requirements.
Development of New Cannabis-Related Products: The company's development of lozenges, balms, and creams represents a growth opportunity. By introducing innovative and targeted products, Dogecoin Cash, Inc. can attract new customers and increase revenue streams. The market for cannabis-infused products is expanding, with consumers seeking various forms of consumption and therapeutic benefits. The timeline for product development and launch depends on research, formulation, and regulatory approvals.
Expansion of the www.cbds.com Website: Dogecoin Cash, Inc.'s plan to offer branded men's and women's fashion apparel through its www.cbds.com website represents a diversification strategy. By leveraging its existing online platform and customer base, the company can tap into the broader e-commerce market. The timeline for launching the fashion apparel line depends on sourcing suppliers, designing products, and setting up the online store. Success in this venture would require effective marketing and branding efforts.
Leveraging Intellectual Property for Edibles: Holding an intellectual property license for the manufacture of medical marijuana edibles provides Dogecoin Cash, Inc. with a unique opportunity. The edibles market is a significant segment of the cannabis industry, offering a discreet and convenient consumption method. By developing and marketing its own line of edibles, the company can capture a share of this growing market. The timeline for launching edibles depends on production capacity, regulatory compliance, and market demand.
Partnerships with Cannabis Dispensaries: Dogecoin Cash, Inc. can explore partnerships with cannabis dispensaries to offer its PrestoDoctor services to their customers. By integrating its telemedicine platform with dispensaries' online or in-store operations, the company can reach a wider audience and streamline the process of obtaining medical marijuana recommendations. The timeline for establishing partnerships depends on negotiations, integration efforts, and mutual benefits.

Market capitalization of $0.00B, indicating a micro-cap company with limited financial resources.
P/E ratio of -1.65, reflecting net losses and potentially unsustainable operations.
Gross margin of 63.4%, suggesting a strong ability to control production costs relative to revenue.
Profit margin of -195.0%, indicating significant operational inefficiencies and high expenses.
Beta of 2.78, indicating high volatility compared to the overall market.

DOGP提供哪些产品和服务？

Provides telemedicine online referral services for customers desiring medical marijuana cards.
Offers PrestoDoctor, an online telemedicine platform connecting patients with physicians.
Facilitates video conferencing for medical marijuana recommendations.
Develops lozenges for relief.
Produces Recover, a deep penetrating healing balm for pain relief.
Creates Trauma Cream, a cream infused with cannabinoids and THC.
Intends to offer branded men's and women's fashion through www.cbds.com.
Holds intellectual property license for manufacture of medical marijuana edibles.

DOGP如何赚钱？

Generates revenue through fees charged for telemedicine consultations on the PrestoDoctor platform.
Sells cannabis-related products, including lozenges, balms, and creams, directly to consumers.
Plans to generate revenue from the sale of branded fashion apparel through its online store.
Potentially licenses its intellectual property for medical marijuana edibles to other companies.

Individuals seeking medical marijuana cards for various health conditions.
Patients looking for convenient and accessible telemedicine consultations.
Consumers interested in cannabis-related products for pain relief and other therapeutic benefits.
Customers of cannabis dispensaries seeking medical marijuana recommendations.
Individuals interested in purchasing branded fashion apparel through the company's online store.

First-mover advantage in providing telemedicine services for medical marijuana recommendations.
Established PrestoDoctor platform with existing user base and physician network.
Intellectual property license for the manufacture of medical marijuana edibles.
Brand recognition within the cannabis telemedicine market.

什么因素可能推动DOGP股价上涨？

Upcoming: Potential expansion of PrestoDoctor into new states legalizing medical marijuana.
Upcoming: Launch of branded men's and women's fashion apparel through www.cbds.com.
Ongoing: Increasing acceptance and legalization of medical marijuana in the United States.
Ongoing: Growing demand for telemedicine services for convenient healthcare access.

DOGP的主要风险是什么？

Potential: Changes in regulations and legal restrictions on cannabis could negatively impact operations.
Potential: Competition from larger and more established telemedicine companies.
Ongoing: Negative P/E ratio and profit margin indicate financial instability.
Potential: Limited access to capital and funding opportunities.
Ongoing: High price volatility and illiquidity due to OTC listing.

DOGP的核心优势是什么？

Established PrestoDoctor platform for telemedicine consultations.
Intellectual property license for medical marijuana edibles.
Focus on the growing cannabis and telemedicine industries.
Direct-to-consumer approach for medical marijuana recommendations.

DOGP的劣势是什么？

Negative P/E ratio and profit margin indicate financial challenges.
Limited operating history and small employee base.
Dependence on evolving regulatory landscape.
Intense competition from established telemedicine providers.

DOGP有哪些机遇？

Expansion into new states as medical marijuana legalization progresses.
Development of new cannabis-related products.
Expansion of the www.cbds.com website to include fashion apparel.
Partnerships with cannabis dispensaries.

DOGP面临哪些威胁？

Changing regulations and legal restrictions on cannabis.
Competition from larger and more established telemedicine companies.
Potential for negative publicity or reputational damage.
Economic downturn impacting consumer spending on cannabis products.

DOGP的竞争对手是谁？

Compass Diversified Holdings — Diversified holding company with investments in various industries, including healthcare. — (CMPD)
Canagold Resources Ltd — Primarily focused on gold exploration, but operates in the broader resource sector. — (CNGGF)
Halyk Savings Bank — Financial institution operating in a different sector. — (HLYK)
IRME — Unknown company - ticker not found. — (IRME)
LL Business Operations AG — Unknown company - ticker not found. — (LLBO)

Key Metrics

MoonshotScore: 46/100

Company Profile

CEO: David Tobias
Headquarters: Mesquite, US
Employees: 4
Founded: 2012

AI Insight

AI analysis pending for DOGP

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Dogecoin Cash, Inc. do?

Dogecoin Cash, Inc. operates primarily in the cannabis telemedicine sector, offering online referral services for individuals seeking medical marijuana cards through its PrestoDoctor platform. This platform connects patients with physicians via video conferencing for medical marijuana recommendations. In addition to its telemedicine services, the company develops and markets cannabis-related products, including lozenges, balms, and creams. Dogecoin Cash, Inc. also intends to expand its offerings to include branded fashion apparel through its online store, www.cbds.com, and holds an intellectual property license for the manufacture of medical marijuana edibles.

What do analysts say about DOGP stock?

As of 2026-03-16, there is no available analyst coverage for Dogecoin Cash, Inc. (DOGP). The company's micro-cap status and OTC listing likely contribute to the lack of analyst attention. Investors should conduct their own thorough research and due diligence before considering an investment in DOGP. Key valuation metrics, such as the P/E ratio of -1.65 and a profit margin of -195.0%, suggest significant financial challenges. Growth considerations include the potential expansion of PrestoDoctor into new states and the launch of new products.

What are the main risks for DOGP?

Dogecoin Cash, Inc. faces several significant risks, including regulatory uncertainty surrounding the cannabis industry, intense competition from established telemedicine providers, and its own financial instability. Changes in regulations and legal restrictions on cannabis could negatively impact the company's ability to operate and generate revenue. The company's negative P/E ratio and profit margin indicate a need for improved financial performance. Additionally, the company's OTC listing and small market capitalization contribute to high price volatility and illiquidity, making it difficult to buy or sell shares at desired prices.